("ReNeuron" or the "Company")
Result of AGM
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at today's Annual General Meeting were duly passed.
ENQUIRIES:
|
ReNeuron |
+44 (0)20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Cowles, Stephanie Watson |
|
|
Stifel Nicolaus Europe Limited |
+44 (0) 20 7710 7600 |
|
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) |
|
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
